Canada - English - Health Canada

pfizer canada ulc - fluorouracil - solution - 50mg - fluorouracil 50mg - antineoplastic agents

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - fluorouracil - solution for injection/infusion - fluorouracil 50 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

pharma regulatory services limited office no.3, edgewater complex, st. julians, stj 3151,, malta - solution for injection/infusion - fluorouracil 50 mg/ml - antineoplastic agents

Canada - English - Health Canada

david bull laboratories (pty) ltd. - fluorouracil - liquid - 50mg - fluorouracil 50mg - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - fluorouracil 50 mg/ml - solution for infusion or injection

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - fluorouracil sodium - solution for inj/inf - 25 mg/ml - pyrimidine analogues

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - fluorouracil 25 mg/ml - solution for injection - 250 mg/10ml - active: fluorouracil 25 mg/ml

Canada - English - Health Canada

sandoz canada incorporated - fluorouracil - solution - 50mg - fluorouracil 50mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

spear dermatology products inc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 5 mg in 1 g - fluououracil cream 0.5% is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. fluorouracil may cause fetal harm when administered to a pregnant woman. fluorouracil is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. no adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. one birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil. animal reproduction studies have not been conducted with fluorouracil cream 0.5%. fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when adm

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluorouracil, quantity: 2500 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.